Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials

• Published in: Ophthalmology (Rochester, Minn.) Vol. 120; no. 10; pp. 2013 - 2022
• Main Authors: Brown, David M., MD, Nguyen, Quan Dong, MD, MSc, Marcus, Dennis M., MD, Boyer, David S., MD, Patel, Sunil, MD, PhD, Feiner, Leonard, MD, PhD, Schlottmann, Patricio G., MD, Rundle, Amy Chen, MS, Zhang, Jiameng, PhD, Rubio, Roman G., MD, Adamis, Anthony P., MD, Ehrlich, Jason S., MD, PhD, Hopkins, J. Jill, MD
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.10.2013
• Subjects: Ophthalmology
• ISSN: 0161-6420; 1549-4713
• DOI: 10.1016/j.ophtha.2013.02.034

Purpose To report 36-month outcomes of RIDE ( NCT00473382 ) and RISE ( NCT00473330 ), trials of ranibizumab in diabetic macular edema (DME). Design Phase III, randomized, multicenter, double-masked, 3-year trials, sham injection–controlled for 2 years. Participants Adults with DME (n=759), baseline best-corrected visual acuity (BCVA) 20/40 to 20/320 Snellen equivalent, and central foveal thickness (CFT) ≥275 μm on optical coherence tomography. Methods Patients were randomized equally (1 eye per patient) to monthly 0.5 mg or 0.3 mg ranibizumab or sham injection. In the third year, sham patients, while still masked, were eligible to cross over to monthly 0.5 mg ranibizumab. Macular laser was available to all patients starting at month 3; panretinal laser was available as necessary. Main Outcome Measures The proportion of patients gaining ≥15 Early Treatment Diabetic Retinopathy Study letters in BCVA from baseline at month 24. Results Visual acuity (VA) outcomes seen at month 24 in ranibizumab groups were consistent through month 36; the proportions of patients who gained ≥15 letters from baseline at month 36 in the sham/0.5 mg, 0.3 mg, and 0.5 mg ranibizumab groups were 19.2%, 36.8%, and 40.2%, respectively, in RIDE and 22.0%, 51.2%, and 41.6%, respectively, in RISE. In the ranibizumab arms, reductions in CFT seen at 24 months were, on average, sustained through month 36. After crossover to 1 year of treatment with ranibizumab, average VA gains in the sham/0.5 mg group were lower compared with gains seen in the ranibizumab patients after 1 year of treatment (2.8 vs. 10.6 and 11.1 letters). Per-injection rates of endophthalmitis remained low over time (∼0.06% per injection). The incidence of serious adverse events potentially related to systemic vascular endothelial growth factor inhibition was 19.7% in patients who received 0.5 mg ranibizumab compared with 16.8% in the 0.3 mg group. Conclusions The strong VA gains and improvement in retinal anatomy achieved with ranibizumab at month 24 were sustained through month 36. Delayed treatment in patients receiving sham treatment did not seem to result in the same extent of VA improvement observed in patients originally randomized to ranibizumab. Ocular and systemic safety was generally consistent with the results seen at month 24. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references.